More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...

Brian Thompson was shot shortly before UnitedHealth was set to hold its annual investors meeting. The charge marks the latest example of how global automakers are struggling in China as local ...

Ozempic promotes weight loss by mimicking the GLP-1 hormone the body naturally produces after eating, so users feel fuller ...

Novavax sells Czech manufacturing facility to Novo Nordisk for $200 million, aiming to cut costs by $80 million annually and ...

Lilly's Zepbound outperforms Novo Nordisk's Wegovy in weight loss study, boosting market-share gains and stock prices.

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...

Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

UnitedHealthcare CEO Brian Thompson was shot outside a Manhattan hotel, with the attack appearing targeted; the assailant ...